Skip to content
value.today

Neos Therapeutics, Inc.

🇺🇸 Grand Prairie, Texas, USAPharmaceuticalsFounded 2009
Total raised
$95 M
6 rounds on record
Latest round
$21 M
Dec 2014
First round on record
Jun 2009
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Neos Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2014$21 MNo. 6$10 to $50 million

Neos Therapeutics, Inc.: Raise no. 6, Dec 2014

Investors in this round

27 investors had bought by the notice of Feb 20, 2015: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Neos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$21 M of $21 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlen Ewart · Executive Officer · Controller
  • Asif Mughal · Executive Officer · VP Quality Assurance
  • Carolyn Sikes · Executive Officer · VP Clinical Affairs
  • Dorothy Engelking · Executive Officer · VP Regulatory Affairs
  • Margaret Cabano · Executive Officer · VP Operations
  • Mark Tengler · Executive Officer · Chief Technology Officer
  • Richard Eisenstadt · Executive Officer · Chief Financial Officer and Secretary
  • Russ McMahen · Executive Officer · VP Research and Development
  • Stacie Switzer · Executive Officer · Assistant Secretary
  • Steven Lutz · Executive Officer · VP Sales
  • Vipin Garg · Executive Officer, Director · President and Chief Executive Officer
  • Alan Heller · Director · Chairman
  • Bryant Fong · Director
  • Edward Schnipper · Director
  • Greg Robitaille · Director
  • Ralph Iannelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Most investors participating in this offering receive warrant with coverage equal to 50% of such investor's amount purchased in this offering.”

Signed by Richard Eisenstadt, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Feb 20, 2015. Read the notice at the SEC.

equity, optionsSEC
Mar 2014$3 MNo. 5$2 to $10 million

Neos Therapeutics, Inc.: Raise no. 5, Mar 2014

Investors in this round

3 investors had bought by the notice of Apr 9, 2014: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Neos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlen Ewart · Executive Officer · Controller
  • Asif Mughal · Executive Officer · VP Quality Assurance
  • Carolyn Sikes · Executive Officer · VP of Clinical Affairs
  • Dorothy Engelking · Executive Officer · VP of Regulatory Affairs
  • Margaret Cabano · Executive Officer · VP Operations
  • Mark Tengler · Executive Officer · Chief Technology Officer
  • Russ McMahen · Executive Officer · VP Research and Development
  • Stacie Switzer · Executive Officer · General Counsel
  • Victor Miller · Executive Officer · VP Finance
  • Alan Heller · Director · Chairman
  • Bryant Fong · Director
  • Edward Schnipper · Director
  • Greg Robitaille · Director
  • Ralph Iannelli · Director
  • Vipin Garg · Director · Chief Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Vipin K. Garg, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 9, 2014. Read the notice at the SEC.

equitySEC
Dec 2013$16 MNo. 4$10 to $50 million

Neos Therapeutics, Inc.: Raise no. 4, Dec 2013

Investors in this round

25 investors had bought by the notice of Mar 4, 2014: 25 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Neos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$16 M of $16 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlen Ewart · Executive Officer · Controller
  • Asif Mughal · Executive Officer · VP Quality Assurance
  • Carolyn Sikes · Executive Officer · VP of Clinical Affairs
  • Dorothy Engelking · Executive Officer · VP of Regulatory Affairs
  • Ellen Hoffing · Executive Officer · Co-President and Chief Operating Officer
  • Margaret Cabano · Executive Officer · VP Operations
  • Mark Tengler · Executive Officer · Co-President and Chief Technology Officer
  • Russ McMahen · Executive Officer · VP Research and Development
  • Stacie Switzer · Executive Officer · General Counsel
  • Victor Miller · Executive Officer · VP Finance
  • Alan Heller · Director · Chairman
  • Bryant Fong · Director
  • Edward Schnipper · Director
  • Greg Robitaille · Director
  • Ralph Iannelli · Director
  • Vipin Garg · Director · Chief Executive Officer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Ellen Hoffing, Co-President and Chief Operating Officer. Source: SEC Form D and 1 amendment, newest notice filed Mar 4, 2014. Read the notice at the SEC.

equitySEC
Jul 2012$18 MNo. 3$10 to $50 million

Neos Therapeutics, Inc.: Raise no. 3, Jul 2012

Investors in this round

41 investors had bought by the notice of Jul 16, 2012: 41 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Neos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$18 M of $30 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlen Ewart · Executive Officer
  • Bryan Hill · Executive Officer
  • Carolyn Sikes · Executive Officer
  • Dorothy Engelking · Executive Officer
  • Ellen Hoffing · Executive Officer
  • Margaret Cabano · Executive Officer
  • Mark Tengler · Executive Officer
  • Mark Van Ausdal · Executive Officer
  • Russ McMahen · Executive Officer
  • Victor Miller · Executive Officer
  • Alan Heller · Director
  • Bryant Fong · Director
  • Christopher Clement · Director
  • Greg Robitaille · Director
  • Karl Handelsman · Director
  • Ralph Iannelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Salem Partners LLC (CRD 43363) · Los Angeles, CaliforniaSold in CA, CO, CT, DC, DE, FL, GA, IL, MA, MD, MI, MN, NC, NJ, NY, PA, TX, VA, WA, WY

Signed by Ellen Hoffing, Co-President and Chief Operating Officer. Source: SEC Form D, newest notice filed Jul 16, 2012. Read the notice at the SEC.

equitySEC
May 2011$14 MNo. 2$10 to $50 million

Neos Therapeutics, Inc.: Raise no. 2, May 2011

Investors in this round

48 investors had bought by the notice of Jun 9, 2011: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Neos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$14 M of $20 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$338,863
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlen Ewart · Executive Officer
  • Bryan Hill · Executive Officer
  • Carolyn Sikes · Executive Officer
  • Dorothy Frank · Executive Officer
  • Ellen Hoffing · Executive Officer
  • Margaret Lokash · Executive Officer
  • Mark Tengler · Executive Officer
  • Mark Van Ausdal · Executive Officer
  • Russ McMahen · Executive Officer
  • Victor Miller · Executive Officer
  • Alan Heller · Director
  • Bryant Fong · Director
  • Christopher Clement · Director
  • Greg Robitaille · Director
  • Karl Handelsman · Director
  • Ralph Iannelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Salem Partners LLC (CRD 43363) · Los Angeles, CaliforniaSold in CA, CO, CT, DC, DE, FL, GA, IL, MA, MD, MI, MN, NC, NJ, NY, PA, TX, VA, WA, WY

Signed by Mark Tengler, Co-President and CTO. Source: SEC Form D, newest notice filed Jun 9, 2011. Read the notice at the SEC.

equitySEC
Jun 2009$24 MNo. 1$10 to $50 million

Neos Therapeutics, Inc.: Raise no. 1, Jun 2009

Investors in this round

57 investors had bought by the notice of Nov 23, 2009: 57 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 23 investors are named for Neos Therapeutics, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$24 M of $50 M offered; $26 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$1,426,700
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Arlen Ewart · Executive Officer
  • Bryan Hill · Executive Officer
  • John Clark · Executive Officer
  • Margaret Lokash · Executive Officer
  • Mark Tengler · Executive Officer
  • Russ McMahen · Executive Officer
  • Alan Heller · Director
  • Bryant Fong · Director
  • Chris Clement · Director
  • Greg Robitaille · Director
  • Karl Handelsman · Director
  • Ralph Iannelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Salem Partners LLC (CRD 43363) · Los Angeles, CaSold in no state named

Signed by Mark Tengler, Co-President and CTO. Source: SEC Form D and 3 amendments, newest notice filed Nov 23, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Neos Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2015).

    SEC Form D · Feb 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Feb 2015

That is all the official record says: Neos Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

23 named in official filings. Open an investor to see everything it has backed.

Investors in Neos Therapeutics, Inc.
InvestorKindAmountRoundRoleSource
Alan L. HellerPersonnot statednot statedHeld Series B, B-1 and C preferred stock, director (Form 3, 2015)SEC Form 3
Burrill Life Scienes Capital Fund III L.P.Fund or asset managernot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
CMEA Ventures VII LPVenture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Cmea Ventures VII (parallel) LPVenture capitalnot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Delaware Street Capital L.P.Fund or asset managernot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Delaware Street Capital Master Fund, L.P.Fund or asset managernot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Dorothy EngelkingPersonnot statednot statedHeld Series C preferred stock (Form 3, 2015)SEC Form 3
DSC Advisors, L.L.C.Fund or asset managernot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
DSC Advisors, L.P.Fund or asset managernot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
DSC Managers, L.L.C.Othernot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Essex Capital CorpFund or asset managernot statednot statedHeld Series A, B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Gregory J. RobitaillePersonnot statednot statedHeld Series B, B-1 and C preferred stock, director (Form 3, 2015)SEC Form 3
Jack W. SchulerPersonnot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Kearny Venture Assoicates II LLCVenture capitalnot statednot statedHeld Series B, B-1 and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Mark TenglerPersonnot statednot statedHeld Series C preferred stock (Form 3, 2015)SEC Form 3
Presidio Partners 2007 GP, LLCFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Presidio Partners 2007 GP, L.P.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2015)SEC Form 3
Vipin K. GargPersonnot statednot statedHeld Series C preferred stock, director (Form 3, 2015)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 57 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Neos Therapeutics, Inc.
NameRoleNamed in
Arlen EwartControllerFeb 2015
Asif MughalVP Quality AssuranceFeb 2015
Carolyn SikesVP Clinical AffairsFeb 2015
Dorothy EngelkingVP Regulatory AffairsFeb 2015
Margaret CabanoVP OperationsFeb 2015
Mark TenglerChief Technology OfficerFeb 2015
Richard EisenstadtChief Financial Officer and SecretaryFeb 2015
Russ McMahenVP Research and DevelopmentFeb 2015
Stacie SwitzerAssistant SecretaryFeb 2015
Steven LutzVP SalesFeb 2015
Vipin GargPresident and Chief Executive OfficerFeb 2015
Victor MillerVP FinanceApr 2014
Ellen HoffingCo-President and Chief Operating OfficerMar 2014
Bryan HillExecutive officerJul 2012
Mark Van AusdalExecutive officerJul 2012
Dorothy FrankExecutive officerJun 2011
Margaret LokashExecutive officerJun 2011
John ClarkExecutive officerNov 2009
Alan HellerChairmanFeb 2015
Bryant FongDirectorFeb 2015
Edward SchnipperDirectorFeb 2015
Greg RobitailleDirectorFeb 2015
Ralph IannelliDirectorFeb 2015
Vipin GargPresident and Chief Executive OfficerFeb 2015
Christopher ClementDirectorJul 2012
Karl HandelsmanDirectorJul 2012
Chris ClementDirectorNov 2009